Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
Tue, 28.07.2020
TLG IMMOBILIEN AG
NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES") OR IN OR INTO OR TO ANY PERS [ … ]
Tue, 28.07.2020
USU Software AG
For the third consecutive year, Aspera is recognized by Gartner for its completeness of vision and ability to execute for its flagship SAM product SmartTrack.Aachen, July 28, 2020 - Aspera, a leading provider of solutions and services for Software Asset Management (SAM), and part of the USU Group, is the sole company to be placed as a Challenger in [ … ]
Tue, 28.07.2020
Vectron Systems AG
- Continued high investments in the digital business
- Demand picks up again
Vectron Systems AG (Vectron), a leading provider of intelligent, digitised POS systems consisting of hardware, software and cloud services, with focus on the catering and bakery trade, has increased sales in the first half of 2020 by 5.0 percent to around EUR 12.6 m [ … ]
Tue, 28.07.2020
FUCHS PETROLUB SE
Supervisory Board extends Stefan Fuchs's Executive Board appointment
The Supervisory Board of FUCHS PETROLUB SE resolved at its meeting today to extend the contract with the Chairman of the Executive Board Stefan Fuchs (52) until June 30, 2026. In this way, FUCHS PETROLUB is ensuring continuity on its Executive Board. Stefan Fuchs has been on the [ … ]
Tue, 28.07.2020
Apogenix AG
Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients
Heidelberg, Germany, July 28, 2020 - Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. [ … ]
Tue, 28.07.2020
Ringmetall Aktiengesellschaft
Ringmetall plans unchanged high dividend due to good business performance
- Business development in the year to date remains on target
- Management Board proposes unchanged dividend of 6 cents per share
- Publication of preliminary half-year figures expected on 6 August
Munich, 28 July 2020 - Ringmetall AG (ISIN: DE0006001902), a leading internat [ … ]
Tue, 28.07.2020
GBA Group Pharma
GBA Group Pharma updates on clinical trial risks following Brexit
- European authorities warn of imminent impact on clinical trial supply chains for companies running EU clinical trials
- QPs for batch release of Investigational Medical Products (IMPs) must be EU-based as of January 1, 2021
- Numerous ongoing and planned clinical studies are a [ … ]
Tue, 28.07.2020
Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies becomes a sponsor of University College London's (UCL) Industry Exchange Network (IXN) Programme
BERLIN/LONDON, July 28, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, was appo [ … ]
Tue, 28.07.2020
PSI Software AG
PSI with Stable New Orders and Sales in First Six Months
- Sales of 104.9 million euros just slightly below previous year
- EBIT with minus 16.4% to 5.4 million euros within the forecast
- Operating cash flow increased by 20.7 million to 19.4 million euros
KPIs (TEUR)
1 Jan. - 30 June 2020
1 Jan. - 30 June 2019
Change
Sales
104,853
[ … ]
Tue, 28.07.2020
HELLA GmbH & Co. KGaA
HELLA publishes preliminary annual figures as well as outlook and presents a programme to strengthen its competitiveness in the long term
- Currency and portfolio-adjusted sales decline by 14.3 percent to € 5.8 billion in fiscal year 2019/2020 based on preliminary figures; adjusted EBIT margin comes to 4.0 percent
- Reported EBIT amounts to minus [ … ]